๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces

Recruitingn/aAges any - anyAllCentral South University
NCT07066813 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are: * What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces ๏ผˆLCCA) and predicting patient outcomes? * How do imaging features of cystic lesions correlate with their pathological characteristics? * What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis? * Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination; 2. Patients who have undergone surgical lung resection; 3. Patients with complete preoperative chest CT imaging data; 4. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor. Exclusion Criteria: 1. History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \[LAM\], or Birt-Hogg-Dubรฉ \[BHD\] syndrome); 2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment; 3. Patients with concurrent other malignancies; 4. Patients with missing or poor-quality preoperative chest CT imaging data.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
The Second Xiangya Hospital of Central South University
Changsha, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy